Skip to main content
SpringerLink
Log in
Book cover

Pharmacology of Ocular Therapeutics pp 207–227Cite as

Ocular Hypotensives and Neuroprotectants in Glaucoma

  • Chapter
  • First Online:

  • 1635 Accesses

Abstract

Glaucoma is the leading cause of blindness in the world. It is an optic neuropathy disease associated with elevated intraocular pressure. Glaucoma encompass a group of various clinical presentations that share the same anatomical feature, a progressive loss of retinal ganglion cells (RGCs) superior to the age-related loss. This chapter deals about the pharmacology of conventional antiglaucoma drugs and newer drugs/pathways which are under investigation. Medical management of glaucoma has been discussed with the concept of reaching target intraocular pressure (“Target IOP”) using pharmacological agents. Newer concept of neuro-protectants for the management of glaucoma has also been included in the deliberations.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Kingman S. Glaucoma is second leading cause of blindness globally. Bull World Health Organ. 2004;82:887–8.

    PubMed Central  PubMed  Google Scholar 

  • George R, Ve RS, Vijaya L. Glaucoma in India: estimated burden of disease. J Glaucoma. 2010;19:391–7.

    Article  PubMed  Google Scholar 

  • Johnstone MA, Albert DM. Prostaglandin –induced hair growth. Surv Opthalmol. 2002;47 Suppl 1:S185–202.

    Article  Google Scholar 

  • Pfeiffer N, Thieme H. Prostaglandin analogues. In: Shaarawy T, Sherwood MB, Crowston JG, Hitchings RA, editors. Glaucoma-medical diagnosis and therapy. London. Elsveir Ltd; 2015. p. 543.

    Google Scholar 

  • Tripathi KD. Essentials of Medical Pharmacology, New Delhi: Jaypee Brothers Medical Publishers. 2008 (5th ed), p.674.

    Google Scholar 

  • Rao PV, Epstein DL. Rho GTPase/Rho kinase as a novel target for the treatment of glaucoma. BioDrugs. 2007;21:167–77.

    Article  CAS  PubMed  Google Scholar 

  • Challa P, Arnold JJ. Rho-kinase inhibitors offer a new approach in the treatment of glaucoma. Expert Opin Investig Drugs. 2014;23(1):81–95.

    Article  CAS  PubMed  Google Scholar 

  • Tanihara H, Inatani M, Honjo M, et al. Intraocular pressure-lowering effects and safety of topical administration of a selective ROCK inhibitor, SNJ-1656, in healthy volunteers. Arch Ophthalmol. 2008;126:309–15.

    Article  CAS  PubMed  Google Scholar 

  • Hahmann C, Schroeter T. Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity. Cell Mol Life Sci. 2010;67(2):171–7.

    Article  CAS  PubMed  Google Scholar 

  • Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268–79.

    Article  PubMed  Google Scholar 

  • Feiner L, Piltz-Seymour JR. Collaborative Initial Glaucoma Treatment Study: a summary of results to date. Curr Opin Ophthalmol. 2003;14:106–11.

    Article  PubMed  Google Scholar 

  • Hodapp E, Parrish 2nd RK, Anderson DR. Clinical decisions in glaucoma. St Louis: Mosby and Co; 1993. p. 63–92.

    Google Scholar 

  • Jampel HD. Target pressure in glaucoma therapy. J Glaucoma. 1997;6:133–8.

    Article  CAS  PubMed  Google Scholar 

  • Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001;108:1943–53.

    Article  CAS  PubMed  Google Scholar 

  • American academy of ophthalmology basic and clinical science course section 10. Glaucoma. 2004–2005.

    Google Scholar 

  • Bito LZ. A new approach to the medical management of glaucoma, from the bench to the clinic, and beyond: the Proctor Lecture. Invest Ophthalmol Vis Sci. 2001;42(6):1126–33.

    CAS  PubMed  Google Scholar 

  • Camras CB, Siebold EC, Lustgarten JS, et al. Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology. 1989;96(9):1329–36; discussion 1336–27.

    Article  CAS  PubMed  Google Scholar 

  • Lim KS, Nau CB, O’Byrne MM, et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 2008;115(5):790–5 e794.

    Article  PubMed Central  PubMed  Google Scholar 

  • Walters TR, DuBiner HB, Carpenter SP, Khan B, VanDenburgh AM. 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol. 2004;49 Suppl 1:S26–35.

    Article  PubMed  Google Scholar 

  • Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group. Ophthalmology. 1995;102(12):1743–52.

    Article  CAS  PubMed  Google Scholar 

  • Sjoquist B, Stjernschantz J. Ocular and systemic pharmacokinetics of latanoprost in humans. Surv Ophthalmol. 2002;47 Suppl 1:S6–12.

    Article  PubMed  Google Scholar 

  • Sharif NA, Kelly CR, Crider JY, Williams GW, Xu SX. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J Ocul Pharmacol Ther. 2003;19(6):501–15.

    Article  CAS  PubMed  Google Scholar 

  • Gross RL, Peace JH, Smith SE, et al. Duration of IOP reduction with travoprost BAK-free solution. J Glaucoma. 2008;17(3):217–22.

    Article  PubMed  Google Scholar 

  • Stewart WC, Kolker AE, Stewart JA, Leech J, Jackson AL. Conjunctival hyperemia in healthy subjects after short-term dosing with latanoprost, bimatoprost, and travoprost. Am J Ophthalmol. 2003;135(3):314–20.

    Article  CAS  PubMed  Google Scholar 

  • Konstas AG, Katsimbris JM, Lallos N, Boukaras GP, Jenkins JN, Stewart WC. Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients. Ophthalmology. 2005;112(2):262–6.

    Article  PubMed  Google Scholar 

  • Goldberg I. Comparison of tropical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma. 2001;10:414–22.

    Article  CAS  PubMed  Google Scholar 

  • Cohen JS, Gross RL, Cheetham JK, VanDenburgh AM, Bernstein P, Whitcup SM. Two-year double-masked comparison of bimatoprost with timolol in patients with glaucoma or ocular hypertension. Surv Ophthalmol. 2004;49 Suppl 1:S45–52.

    Article  PubMed  Google Scholar 

  • Bayer A, Weiler W, Oeverhaus U, Skrotzki FE, Stewart WC. Two year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. J Ocul Pharmacol Ther. 2004;20(6):470–8.

    Article  CAS  PubMed  Google Scholar 

  • Boger III WP. Short term “escape” and long term “drift”: the dissipation effects of the beta adrenergic agents. Surv Ophthalmol. 1983;28(Suppl):235–42.

    Article  PubMed  Google Scholar 

  • Gieser SC, Juzych M, Robin AL, et al. Clinical pharmacology of adrenergic drugs. In: Ritch R, Shields MB, Krupin T, editors. The glaucomas. St. Louis: Mosby; 1996.

    Google Scholar 

  • Allingham RR, Damji K, Freedman S, et al. Adrenergic receptor antagonists. In: Shield’s textbook of glaucoma. Philadelphia: Lippincott Williams and Wilkins; 2005.

    Google Scholar 

  • Dunham CN, Spaide RF, Dunham G. The contralateral reduction of intraocular pressure by timolol. Br J Ophthalmol. 1994;78:38–40.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Fechtner RD. Beta blockers. In: Netland PA, Allen RC, editors. Glaucoma medical therapy principles and management. San Francisco: The Foundation of the American Academy of Ophthalmology; 1999.

    Google Scholar 

  • Reitsamer HA, Posey M, Kiel JW. Effects of a topical alpha2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits. Exp Eye Res. 2006;82(3):405–15.

    Article  CAS  PubMed  Google Scholar 

  • Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128(1):8–14.

    Article  CAS  PubMed  Google Scholar 

  • Yuksel N, Guler C, Caglar Y, Elibol O. Apraclonidine and clonidine: a comparison of efficacy and side effects in normal and ocular hypertensive volunteers. Int Ophthalmol. 1992;16(4–5):337–42.

    Article  CAS  PubMed  Google Scholar 

  • Whitson JT, Ochsner KI, Moster MR, et al. The safety and intraocular pressure-lowering efficacy of brimonidine tartrate 0.15% preserved with polyquaternium-1. Ophthalmology. 2006;113(8):1333–9.

    Article  PubMed  Google Scholar 

  • Mungan NK, Wilson TW, Nischal KK, Koren G, Levin AV. Hypotension and bradycardia in infants after the use of topical brimonidine and beta-blockers. J AAPOS. 2003;7(1):69–70.

    Article  PubMed  Google Scholar 

  • Schuman JS. Short- and long-term safety of glaucoma drugs. Expert Opin Drug Saf. 2002;1(2):181–94.

    Article  CAS  PubMed  Google Scholar 

  • Matsui H, Murakami M, Wynns GC, et al. Membrane carbonic anhydrase (IV) and ciliary epithelium. Carbonic anhydrase activity is present in the basolateral membranes of the non-pigmented ciliary epithelium of rabbit eyes. Exp Eye Res. 1996;62(4):409–17.

    Article  CAS  PubMed  Google Scholar 

  • Turtz CA, Turtz AI. Toxicity due to acetazolamide (diamox). AMA Arch Ophthalmol. 1958;60(1):130–1.

    Article  CAS  PubMed  Google Scholar 

  • Michaud JE, Friren B, International Brinzolamide Adjunctive Study Group. Comparison of topical brinzolamide 1% and dorzolamide 2% eye drops given twice daily in addition to timolol 0.5% in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132(2):235–43.

    Article  CAS  PubMed  Google Scholar 

  • Siesky B, Harris A, Cantor LB, et al. A comparative study of the effects of brinzolamide and dorzolamide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma. Br J Ophthalmol. 2008;92(4):500–4.

    Article  CAS  PubMed  Google Scholar 

  • Friedland BR, Mallonee J, Anderson DR. Short-term dose response characteristics of acetazolamide in man. Arch Ophthalmol. 1977;95(10):1809–12.

    Article  CAS  PubMed  Google Scholar 

  • Alward WL. Medical management of glaucoma. N Engl J Med. 1998;339(18):1298–307.

    Article  CAS  PubMed  Google Scholar 

  • Sweeney KR, Chapron DJ, Brandt JL, Gomolin IH, Feig PU, Kramer PA. Toxic interaction between acetazolamide and salicylate: case reports and a pharmacokinetic explanation. Clin Pharmacol Ther. 1986;40(5):518–24.

    Article  CAS  PubMed  Google Scholar 

  • Bateson MC, Lant AF. Dietary potassium and diuretic therapy. Lancet. 1973;2(7825):381–2.

    Article  CAS  PubMed  Google Scholar 

  • Worthen DM. Effect of pilocarpine drops on the diurnal intraocular pressure variation in patients with glaucoma. Invest Ophthalmol. 1976;15:784–7.

    CAS  PubMed  Google Scholar 

  • Quigley HA, Pollack IP. Intraocular pressure control with twice daily pilocarpine in two vehicle solutions. Ann Ophthalmol. 1977;9:427–30.

    CAS  PubMed  Google Scholar 

  • Van Hoose MC, Leaders FE. The role of cornea in biological response to pilocarpine. Invest Ophthalmol. 1974;13:377–83.

    PubMed  Google Scholar 

  • Zimmerman TJ, Wheeler TM. Miotics: side effects and ways to avoid them. Ophthalmology. 1982;89(1):76–80.

    Article  CAS  PubMed  Google Scholar 

  • Pape LG, Forbes M. Retinal detachment and miotic therapy. Am J Ophthalmol. 1978;85(4):558–66.

    Article  CAS  PubMed  Google Scholar 

  • Eilderton TE, Farmati O, Zsigmond EK. Reduction in plasma cholinesterase levels after prolonged administration of echothiophate iodide eyedrops. Can Anaesth Soc J. 1968;15(3):291–6.

    Article  CAS  PubMed  Google Scholar 

  • Singh A. Medical therapy of glaucoma. Ophthalmol Clin North Am. 2005;18:397–408.

    Article  PubMed  Google Scholar 

  • McCurdy DK, Schneider B, Scheie HG. Oral glycerol: the mechanism of intraocular hypotension. Am J Ophthalmol. 1966;61:1244–9.

    Article  CAS  PubMed  Google Scholar 

  • Danesh-Meyer HV, Levin LA. Neuroprotection: extrapolating from neurologic diseases to the eye. Am J Ophthalmol. 2009;148(2):186–91 e182.

    Article  PubMed  Google Scholar 

  • Chang EE, Goldberg JL. Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement. Ophthalmology. 2012;119(5):979–86.

    Article  PubMed Central  PubMed  Google Scholar 

  • Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol. 1998;126(4):487–97.

    Google Scholar 

  • The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS investigators. Am J Ophthalmol. 2000;130(4):429–40.

    Google Scholar 

  • Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol. 2003;121(1):48–56.

    Article  PubMed  Google Scholar 

  • Osborne NN. Pathogenesis of ganglion “cell death” in glaucoma and neuroprotection: focus on ganglion cell axonal mitochondria. Prog Brain Res. 2008;173:339–52.

    Article  CAS  PubMed  Google Scholar 

  • Shih GC, Calkins DJ. Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action. Expert Rev Ophthalmol. 2012;7(2):161–75.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Limb GA, Martin KR. Current prospects in optic nerve protection and regeneration: sixth ARVO/Pfizer Ophthalmics Research Institute conference. Invest Ophthalmol Vis Sci. 2011;52(8):5941–54.

    Article  PubMed  Google Scholar 

  • Quigley HA. Clinical trials for glaucoma neuroprotection are not impossible. Curr Opin Ophthalmol. 2012;23(2):144–54.

    Article  PubMed  Google Scholar 

  • Baltmr A, Duggan J, Nizari S, Salt TE, Cordeiro MF. Neuroprotection in glaucoma – is there a future role? Exp Eye Res. 2010;91(5):554–66.

    Article  CAS  PubMed  Google Scholar 

  • Osborne NN, Chidlow G, Nash MS, Wood JP. The potential of neuroprotection in glaucoma treatment. Curr Opin Ophthalmol. 1999a;10(2):82–92.

    Article  CAS  PubMed  Google Scholar 

  • Osborne NN, Ugarte M, Chao M, et al. Neuroprotection in relation to retinal ischemia and relevance to glaucoma. Surv Ophthalmol. 1999b;43 Suppl 1:S102–28.

    Article  PubMed  Google Scholar 

  • Newman NJ, Biousse V, David R, et al. Prophylaxis for second eye involvement in leber hereditary optic neuropathy: an open-labeled, nonrandomized multicenter trial of topical brimonidine purite. Am J Ophthalmol. 2005;140(3):407–15.

    CAS  PubMed  Google Scholar 

  • Wilhelm B, Ludtke H, Wilhelm H. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. Graefes Arch Clin Exp Ophthalmol. 2006;244(5):551–8.

    Article  CAS  PubMed  Google Scholar 

  • Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S. A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol. 2011;151(4):671–81.

    Article  CAS  PubMed  Google Scholar 

  • Cordeiro MF, Levin LA. Clinical evidence for neuroprotection in glaucoma. Am J Ophthalmol. 2011;152(5):715–6.

    Article  PubMed Central  PubMed  Google Scholar 

  • Hare WA, WoldeMussie E, Lai RK, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: functional measures. Invest Ophthalmol Vis Sci. 2004a;45(8):2625–39.

    Article  PubMed  Google Scholar 

  • Hare WA, WoldeMussie E, Weinreb RN, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: structural measures. Invest Ophthalmol Vis Sci. 2004b;45(8):2640–51.

    Article  PubMed  Google Scholar 

  • Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med. 2003;348(14):1333–41.

    Article  CAS  PubMed  Google Scholar 

  • Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol. 2009;87(4):450–4.

    Article  PubMed  Google Scholar 

  • Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev. 2010;2:CD006539.

    Google Scholar 

  • Scozzafava A, Supuran CT, Glaucoma and the applications of carbonic anhydrase inhibitors. Subcell Biochem. 2014;75:349–59.

    Article  CAS  PubMed  Google Scholar 

  • Levin LA, Danesh-Meyer HV. Lost in translation: bumps in the road between bench and bedside. JAMA. 2010;303(15):1533–4.

    Article  CAS  PubMed  Google Scholar 

  • Wang SK, Chang RT. An emerging treatment option for glaucoma: Rho kinase inhibitors. Clin Ophthalmol. 2014;8:883–90.

    PubMed Central  CAS  PubMed  Google Scholar 

  • Bausch + Lomb and Nicox’s Glaucoma Candidate VESNEO: http://ir.valeant.com/investor-relations/news-releases/news-release-details/2014/Bausch--Lomb-and-Nicoxs-Glaucoma-Candidate-VESNEO-latanoprostene-bunod-Meets-Primary-Endpoint-in-Phase-3-Studies/default.aspx

  • Yang H, Leffler CT. Hybrid dendrimer hydrogel/poly(lactic-co-glycolic acid) nanoparticle platform: an advanced vehicle for topical delivery of antiglaucoma drugs and a likely solution to improving compliance and adherence in glaucoma management. J Ocul Pharmacol Ther. 2013;29(2):166–72.

    Article  PubMed  Google Scholar 

  • Fulgencio Gde O, Viana FA, Ribeiro RR, Yoshida MI, Faraco AG, Cunha-Junior Ada S. New mucoadhesive chitosan film for ophthalmic drug delivery of timolol maleate: in vivo evaluation. J Ocul Pharmacol Ther. 2012;28(4):350–8.

    Article  PubMed  Google Scholar 

  • Manickavasagam D, Oyewumi MO. Critical assessment of implantable drug delivery devices in glaucoma management. J Drug Deliv. 2013;2013:895013.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Dr. Rajendra Prasad Center for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India

    Tanuj Dada MD (Professor)

  2. Glaucoma and Neuro-ophthalmology Services, Department of Ophthalmology, Government Medical College and Hospital, Chandigarh, India

    Parul Ichhpujani MD

  3. Department of Ocular Pharmacology, Aravind Medical Research Foundation (AMRF), Madurai, Tamil Nadu, India

    Srinivasan Senthilkumari PhD

  4. Department of Ophthalmology, University Hospital, Dijon, France

    Alain Bron MD

Authors
  1. Tanuj Dada MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Parul Ichhpujani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Srinivasan Senthilkumari PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alain Bron MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Srinivasan Senthilkumari PhD .

Editor information

Editors and Affiliations

  1. Ocular Pharmacology and Pharmacy, Dr. RP Centre for Ophthalmic Sciences, New Delhi, India

    Thirumurthy Velpandian

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Dada, T., Ichhpujani, P., Senthilkumari, S., Bron, A. (2016). Ocular Hypotensives and Neuroprotectants in Glaucoma. In: Velpandian, T. (eds) Pharmacology of Ocular Therapeutics. Adis, Cham. https://doi.org/10.1007/978-3-319-25498-2_7

Download citation

Publish with us

Policies and ethics

Search

Navigation